Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $992M | $1.19B | $1.47B | $1.52B | $1.37B | $1.54B | $1.56B | $1.54B | $1.61B | $1.64B |
| Revenue growth | — | 19.8% | 23.9% | 3.1% | -9.6% | 12.4% | 1.0% | -1.0% | 4.5% | 1.5% |
| Gross profit | $643M | $753M | $901M | $953M | $851M | — | — | — | — | — |
| Gross margin | 64.8% | 63.3% | 61.2% | 62.8% | 62.0% | — | — | — | — | — |
| Operating income | $115M | $44.8M | $111M | $93.8M | $151M | $197M | $239M | $112M | $28.4M | -$493M |
| Operating margin | 11.6% | 3.8% | 7.5% | 6.2% | 11.0% | 12.8% | 15.3% | 7.2% | 1.8% | -30.2% |
| Net income | $74.6M | $64.7M | $60.8M | $50.2M | $134M | $169M | $181M | $67.7M | -$6.94M | -$516M |
| Net margin | 7.5% | 5.4% | 4.1% | 3.3% | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
| EPS (diluted) | $0.94 | $0.82 | $0.72 | $0.58 | $1.57 | $1.98 | $2.16 | $0.84 | -$0.09 | -$6.74 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $116M | $115M | $200M | $231M | $204M | $312M | $264M | $140M | $129M | $50.4M |
| Capital expenditures | $47.3M | $43.5M | $77.7M | $69.5M | $38.9M | $48.0M | $42.3M | $66.9M | $104M | $81.4M |
| Free cash flow | $69.1M | $71.0M | $122M | $162M | $165M | $264M | $222M | $73.1M | $25.0M | -$31.1M |
| Share buybacks | — | — | $0.00 | $0.00 | $100M | $0.00 | $125M | $275M | $52.5M | $221K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $102M | $175M | $139M | $199M | $470M | $513M | $457M | $276M | $246M | $235M |
| Total assets | $1.81B | $3.21B | $3.11B | $3.30B | $3.62B | $3.78B | $3.89B | $3.78B | $4.04B | $3.60B |
| Total liabilities | $968M | $2.25B | $1.73B | $1.89B | $2.10B | $2.10B | $2.09B | $2.19B | $2.49B | $2.56B |
| Long-term debt | — | — | $900M | $878M | $878M | $844M | $775M | $775M | $760M | $727M |
| Shareholders' equity | $840M | $962M | $1.38B | $1.42B | $1.51B | $1.68B | $1.80B | $1.59B | $1.55B | $1.04B |
| Retained earnings | $220M | $285M | $348M | $399M | $532M | $699M | $879M | $947M | $940M | $423M |
| Shares (wtd avg diluted) | 79.2M | 79.1M | 84.0M | 86.5M | 85.2M | 85.5M | 83.5M | 80.3M | 77.0M | 76.7M |
Every figure is extracted from INTEGRA LIFESCIENCES HOLDINGS CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.